DalCor To Develop Failed Roche CETP Inhibitor In Genetic Subgroup
This article was originally published in Scrip
Executive Summary
DalCor Pharmaceuticals has raised $150m via a private financing in order to pick up development of ex-Roche CETP inhibitor dalcetrapib for a genetically distinct group of acute coronary syndromes (ACS) patients.
You may also be interested in...
DalCor Keeps Faith In CETP Biomarker, Despite No Dice For Merck's REVEAL Genetic Analysis
Hopes for a precision approach for the vast cardiovascular disease population live on – past failed studies of HDL-raising drugs and lack of evidence for genetic typing in Merck's latest analysis of anacetrapib in REVEAL.
Merck Calls It Quits On Anacetrapib
Despite success in REVEAL outcomes trial, Merck will not submit the for the cholesteryl ester transfer protein (CETP) inhibitor for regulatory approval.
Merck Calls It Quits On Anacetrapib
Despite the success in the REVEAL outcomes trial for the cholesteryl ester transfer protein (CETP) inhibitor, Merck will not submit the cholesterol therapy for regulatory approval.